REXAM
New French production unit now operational / Expansion of La Verpilliere site for healthcare products / German production capacity expanded
 The La Verpillière site has been expanded primarily for the production of insulin injection pens for US pharma Eli Lilly (Photo: Rexam) |
In early October, UK packaging specialist Rexam (London; www.rexam.com) celebrated the expansion of its production site in southeastern France at La Verpillière – see Plasteurope.com of 22.02.2013. The new production and packaging unit allows for the continuation of its cooperation with Lilly Laboratories, explained Rexam. Since 2008, Rexam Healthcare has been the European supplier of the sub-sets used for the manufacture of insulin injection pens from US pharmaceutical specialist Eli Lilly (Indianapolis, Indiana; www.lilly.com).
The production site in La Verpillière, with 300 employees, covers an area of more than 17,000 m² for production, including 11,300 m² of clean rooms. The completed extension involved adding 3,700 m² with 2,400 m² of clean rooms at Level 8 according to ISO 14644 and is dedicated entirely to producing components for the pen. Rexam said the investment required EUR 15m over three years and, as part of the extension, has added 100 jobs since 2008 through 2014.
The insulin pens are made of ten plastic parts with a metal spring and involves two sub-sets to produce the final product: a dosage selection mechanism and a protective cap. At its French production site in Fegersheim, near Strasbourg, Eli Lilly produces the glass cartridges filled with insulin and assembles the pens used for treating diabetes.
In addition to its activities in France, Rexam Healthcare also announced not long ago – in August – investment plans for its German site in Neuenburg, which opened in 1999 and which Rexam calls a "flagship facility". The company said it will add a new production line involving several injection moulding machines and the addition of 50 new jobs. Neuenburg, in the tri-border region with France and Switzerland, has more than 490 employees and is used for the production of primary packaging such as tubes, tablet dispensers, dosing systems for nasal sprays and eye drops as well as components for insulin pens and diagnostic instruments for medical applications. The production area covers a total of 21,000 m² and includes six production halls, 8,000 m² of clean rooms, more than 100 injection moulding machines and about 40 assembly lines and printing machinery for plastic parts.
In June, CEO Graham Chipchase announced his company's plans to sell the healthcare business, which includes 14 production sites and more than 3,000 employees, to better focus on the manufacture of beverage cans and maximising shareholder value – see Plasteurope.com of 27.06.2013.
The production site in La Verpillière, with 300 employees, covers an area of more than 17,000 m² for production, including 11,300 m² of clean rooms. The completed extension involved adding 3,700 m² with 2,400 m² of clean rooms at Level 8 according to ISO 14644 and is dedicated entirely to producing components for the pen. Rexam said the investment required EUR 15m over three years and, as part of the extension, has added 100 jobs since 2008 through 2014.
The insulin pens are made of ten plastic parts with a metal spring and involves two sub-sets to produce the final product: a dosage selection mechanism and a protective cap. At its French production site in Fegersheim, near Strasbourg, Eli Lilly produces the glass cartridges filled with insulin and assembles the pens used for treating diabetes.
In addition to its activities in France, Rexam Healthcare also announced not long ago – in August – investment plans for its German site in Neuenburg, which opened in 1999 and which Rexam calls a "flagship facility". The company said it will add a new production line involving several injection moulding machines and the addition of 50 new jobs. Neuenburg, in the tri-border region with France and Switzerland, has more than 490 employees and is used for the production of primary packaging such as tubes, tablet dispensers, dosing systems for nasal sprays and eye drops as well as components for insulin pens and diagnostic instruments for medical applications. The production area covers a total of 21,000 m² and includes six production halls, 8,000 m² of clean rooms, more than 100 injection moulding machines and about 40 assembly lines and printing machinery for plastic parts.
In June, CEO Graham Chipchase announced his company's plans to sell the healthcare business, which includes 14 production sites and more than 3,000 employees, to better focus on the manufacture of beverage cans and maximising shareholder value – see Plasteurope.com of 27.06.2013.
31.10.2013 Plasteurope.com [226705-0]
Published on 31.10.2013
German version of this article...